Sinovac Signs Agreement With Bio Farma Indonesia For Covid-19 Vaccine Cooperation

Covid-19 vaccine concentrate requires a series of tests and must be registered with the Indonesian Food and Drug Surveillance Agency prior to mass production. Indonesian President Joko Widodo said the government wants to carry out mass vaccinations by the end of this year. In addition to the partnership with Sinovac, Indonesia has also secured potential CONTREVID 19 vaccines manufactured by Chinese companies CanSino Biologics and China National Pharmaceutical Group, also known as Sinopharm, as well as abu Dhabi-based artificial intelligence and cloud computing company Group 42 and global pharmaceutical company AstraZeneca. Indonesia`s state-owned pharmaceutical company Bio Farma and China`s Sinovac Biotech are conducting the third phase of clinical trials with CoronaVac, one of the World Health Organization`s declared COVID-19 vaccine candidates. The government is also looking for a possible partnership with Chinese pharmaceutical company Sinopharm Group, Secretary of State Retno Marsudi said friday on her Twitter account. Yanuardi Syukur, a professor of social anthropology at Khairun University in Indonesia`s Northern Maluku province, said the collaboration between Bio Farma and Sinovac will strengthen the partnership between Chinese and Indonesian scientists, while working together to develop the “best vaccine” against the new coronavirus. A partnership between China and Indonesia on vaccine development could prove to be a “Game Changer” in the fight against the coronavirus pandemic, analysts said. The arrival of the first batch of CoronaVac is part of an agreement between Indonesia and Sinovac, the country testing the vaccine since August as part of a late-stage clinical trial. The production of a safe and effective vaccine is part of Indonesia`s campaign against the pandemic, as the number of infections in the country has risen to more than 540,000 – the highest in Southeast Asia. While BPOM awaits the results of the clinical trial in Indonesia and other countries, which should be known at the end of January, the government has begun preparing the distribution of vaccines throughout the archipelago. She expects that “a clinical trial scientifically based on COVID-19 will be conducted with the strength that matches the reputation of both companies and the results of the study will soon be presented to the scientific world and regulators after the study is completed.” JAKARTA: Indonesia adopted, on December 6, 1.2 million doses of COVID 19 vaccine will receive from Chinese biotech Sinovac and this month will receive raw materials for the production of 15 million doses from the same company. .

. .